Soyer N.Ali R.Turgut M.Haznedaroğlu İ.C.Yilmaz F.Aydoğdu İ.Pir A.Karakuş V.Özgür G.Kiş C.Ceran F.Ilhan G.Özkan M.Aslaner M.Ince İ.Yavaşoğlu İ.Gediz F.Sönmez M.Güvenç B.Özet G.Kaya E.Vural F.Şahin F.Töbü M.Durusoy R.Saydam G.2024-07-222024-07-22202113000144http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/13604Background/aim: The aim of this study is to assess the efficacy and safety of ruxolitinib in patients with myelofibrosis. Materials and methods: From 15 centers, 176 patients (53.4% male, 46.6% female) were retrospectively evaluated. Results: The median age at ruxolitinib initiation was 62 (28–87) and 100 (56.8%) of all were diagnosed as PMF. Constitutional symptoms were observed in 84.7%. The median initiation dose of ruxolitinib was 30 mg (10–40). Dose change was made in 69 (39.2%) patients. Forty seven (35.6%) and 20 (15.2%) of 132 patients had hematological and nonhematological adverse events, respectively. The mean spleen sizes before and after ruxolitinib treatment were 219.67 ± 46.79 mm versus 199.49 ± 40.95 mm, respectively (p < 0.001). There was no correlation between baseline features and subsequent spleen response. Overall survival at 1-year was 89.5% and the median follow up was 10 (1–55) months. We could not show any relationship between survival and reduction in spleen size (p = 0.73). Conclusion: We found ruxolitinib to be safe, well tolerated, and effective in real-life clinical practice in Turkey. Ruxolitinib dose titration can provide better responses in terms of not only clinical benefit but also for long term of ruxolitinib treatment. © TÜBİTAK.EnglishAll Open Access; Bronze Open Access; Green Open AccessFemaleHumansMaleNitrilesPrimary MyelofibrosisPyrazolesPyrimidinesRetrospective StudiesTurkeynitrilepyrazole derivativepyrimidine derivativeruxolitinibclinical trialfemalehumanmalemulticenter studymyeloid metaplasiaretrospective studyturkey (bird)Article10.3906/sag-1812-70